Table 4.

Mean Change from Baseline to End of Study (Standard Error) of RQLQ Scores for ICX72 and Placebo Groups

Domain of RQLQ scores	ICX72 (N = 20)			Placebo (N = 22)
	Baseline	Change: baseline-end	% Rel change	Baseline	Change: baseline-end	% Rel change
Activities	3.1 (0.3)	1.3 (0.4)	41%	4.1 (0.2)	1.0 (0.4)	21%
Sleep	2.4 (0.3)	1.0 (0.3)	43%	3.2 (0.3)	0.6 (0.3)	18%
Non-nasal/eye symptoms	2.4 (0.3)	1.1 (0.3)	45%	3.3 (0.2)	0.7 (0.3)	21%
Practical problems	2.3 (0.3)	1.0 (0.3)	43%	3.4 (0.4)	0.4 (0.4)	13%
Nasal symptoms	2.4 (0.2)	0.8 (0.3)	32%	3.2 (0.2)	0.5 (0.2)	15%
Eye symptoms	1.8 (0.2)	0.6 (0.2)	31%	2.6 (0.3)	0.7 (0.3)	25%
Emotional factors	1.9 (0.3)	0.9 (0.3)	47%	3.0 (0.2)	0.8 (0.2)	27%
Combined domains	2.3 (0.2)	0.9 (0.2)	41%	3.2 (0.2)	0.7 (0.2)	20%

Abbreviation: N, number of patients.

Lower RQLQ scores indicate improvement in quality of life.

For each domain, baseline differences between groups were significantly different, except for the Sleep domain. Mean changes from baseline to end of study of each domain were not significantly different. Percent relative change of each domain was larger for ICX72, compared with placebo.